{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041568","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.615453+00:00","generated_at":"2026-06-04T04:30:54.377305+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Carisma Therapeutics reports $86.9M net loss; prioritizes CT-0525, cuts workforce 37%","bullets":["Cash of $77.6M as of Dec 31, 2023, expected to fund operations into Q3 2025 after restructuring.","R&D expenses were $74.1M in 2023 (up from $56.6M); net loss $86.9M vs $61.2M in 2022.","Prioritizing CT-0525 (anti-HER2 CAR-Monocyte); ceasing new enrollment in CT-0508 study; pausing CT-1119.","Workforce reduction of ~37% in Q2 2024 as part of pipeline reprioritization and cost savings.","Appointed John Hohneker, M.D. to board, effective April 1, 2024; Chidozie Ugwumba resigned."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041568","json":"https://secwatch.observer/filing/0001104659-24-041568.json","markdown":"https://secwatch.observer/filing/0001104659-24-041568.md","text":"https://secwatch.observer/filing/0001104659-24-041568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/0001104659-24-041568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/tm2410111d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:30:54.377305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84780d8f2a9854e7451ab9073c99bc135765921e","claim":"Carisma Therapeutics Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/0001104659-24-041568-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}